<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003194</url>
  </required_header>
  <id_info>
    <org_study_id>CHMC-6006</org_study_id>
    <secondary_id>CDR0000066029</secondary_id>
    <secondary_id>FHCRC-1244.00</secondary_id>
    <secondary_id>NCI-G98-1373</secondary_id>
    <nct_id>NCT00003194</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study of Thiotepa in Combination With Carboplatin and Topotecan With Peripheral Blood Progenitor Cell Support for the Treatment of Children With Recurrent or Refractory Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy and peripheral&#xD;
      stem cell transplantation in treating patients who have recurrent or refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of thiotepa in combination with carboplatin and&#xD;
           topotecan with peripheral blood stem cell transplantation in patients with recurrent or&#xD;
           refractory pediatric solid tumors.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of thiotepa.&#xD;
&#xD;
      Patients may receive 2 courses of mobilization comprising cyclophosphamide and etoposide with&#xD;
      filgrastim (G-CSF) support and peripheral blood stem cell (PBSC) collection.&#xD;
&#xD;
      Patients receive thiotepa IV over 2 hours on days 0 and 1; topotecan IV over 30 minutes on&#xD;
      days 0-4; and carboplatin IV over 2 hours on days 2 and 3. Patients also receive G-CSF&#xD;
      beginning on day 5, 24-36 hours following the last dose of topotecan. PBSC are reinfused on&#xD;
      day 6 (36-48 hours following the last dose of topotecan) of each course of therapy. Patients&#xD;
      receive 3 courses of therapy.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of thiotepa until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 1 and 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 24 patients will be accrued into this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study enrollment did not meet expected goals&#xD;
  </why_stopped>
  <start_date>July 1997</start_date>
  <completion_date type="Actual">December 19, 2002</completion_date>
  <primary_completion_date type="Actual">December 19, 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven recurrent or refractory pediatric solid tumor&#xD;
&#xD;
          -  Bone marrow metastases allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  1 to 30&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3 (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL (RBC transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  SGOT no greater than 2.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Adequate renal function as defined by one of the following:&#xD;
&#xD;
               -  GFR by creatinine clearance&#xD;
&#xD;
               -  Radioisotope GFR&#xD;
&#xD;
               -  Iothalamate at least 70 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Adequate cardiac function as defined by one of the following:&#xD;
&#xD;
               -  Ejection fraction at least 55% by MUGA&#xD;
&#xD;
               -  Fractional shortening at least 28% by echocardiogram&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  Adequate CNS function as defined by:&#xD;
&#xD;
               -  Seizure disorder, if present, controlled by anticonvulsants&#xD;
&#xD;
               -  CNS toxicity no greater than grade 2&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled infections&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No allergy to platinum compounds&#xD;
&#xD;
          -  No history of allergy to etoposide (unless mobilization phase not required)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 1 week since prior cytokines&#xD;
&#xD;
          -  At least 3 months since prior bone marrow or peripheral blood stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  No concurrent immunomodulator&#xD;
&#xD;
          -  No concurrent cytokines&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks (6 for nitrosourea) since prior chemotherapy and recovered&#xD;
&#xD;
          -  No prior thiotepa&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior total body irradiation conditioning&#xD;
&#xD;
          -  No concurrent radiotherapy to greater than 10% of total liver, lung, or bone marrow&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Hawkins, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Doug Hawkins</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

